Mirum Pharmaceuticals, Inc. $MIRM Shares Acquired by Profund Advisors LLC

Profund Advisors LLC increased its stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 257.6% during the 4th quarter, Holdings Channel reports. The fund owned 27,091 shares of the company’s stock after purchasing an additional 19,515 shares during the quarter. Profund Advisors LLC’s holdings in Mirum Pharmaceuticals were worth $2,140,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of MIRM. Comerica Bank raised its stake in Mirum Pharmaceuticals by 45.1% in the first quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Mirum Pharmaceuticals by 307.3% during the first quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock worth $2,211,000 after purchasing an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock worth $1,176,000 after purchasing an additional 1,720 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Mirum Pharmaceuticals during the first quarter worth about $217,000. Finally, Empowered Funds LLC increased its position in shares of Mirum Pharmaceuticals by 15.4% during the first quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock worth $1,729,000 after purchasing an additional 5,120 shares in the last quarter.

Mirum Pharmaceuticals Trading Up 0.2%

Shares of Mirum Pharmaceuticals stock opened at $95.65 on Wednesday. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. Mirum Pharmaceuticals, Inc. has a 1 year low of $42.89 and a 1 year high of $114.99. The company has a market capitalization of $5.83 billion, a P/E ratio of -7.03 and a beta of 0.52. The business has a 50 day moving average price of $95.71 and a 200 day moving average price of $87.97.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative return on equity of 11.28% and a negative net margin of 140.24%.The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. The company’s revenue for the quarter was up 43.3% on a year-over-year basis. Sell-side analysts anticipate that Mirum Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on MIRM. HC Wainwright set a $185.00 price target on Mirum Pharmaceuticals in a report on Thursday, May 7th. Morgan Stanley lifted their price objective on Mirum Pharmaceuticals from $130.00 to $140.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. TD Cowen boosted their price target on Mirum Pharmaceuticals from $125.00 to $145.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Leerink Partners decreased their price target on Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Finally, Wolfe Research initiated coverage on Mirum Pharmaceuticals in a research note on Tuesday. They set an “outperform” rating and a $145.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.08.

Insider Activity

In related news, CEO Christopher Peetz sold 40,985 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total transaction of $3,769,800.30. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at $17,872,541.82. The trade was a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Peter Radovich sold 16,515 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $1,519,049.70. Following the transaction, the chief operating officer owned 40,272 shares of the company’s stock, valued at $3,704,218.56. This represents a 29.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 76,806 shares of company stock worth $7,064,616. 22.87% of the stock is owned by corporate insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.